Physician profile
Amanda E Allmaras
NPI 1184063000
$5,157.11
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,042 · 2022: $1,781 · 2023: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $844.25 | 2021-2023 | |
| Lilly USA, LLC | $569.22 | 2021-2023 | Mounjaro, Jardiance |
| Amgen INC. | $464.94 | 2021-2023 | Evenity, Prolia, Repatha |
| Pfizer INC. | $428.96 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.63 | 2021-2023 | |
| Astellas Pharma US INC | $248.40 | 2022-2023 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $205.84 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.61 | 2021-2023 | Jardiance, Synjardy |
| Lundbeck LLC | $182.04 | 2021-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $176.40 | 2021-2022 | |
| Novo Nordisk INC | $153.45 | 2021-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $148.49 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.94 | 2021 | |
| Amarin Pharma, INC. | $135.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $135.71 | 2021-2023 | Belsomra, Verquvo, Steglatro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.12 | 2021-2023 | Farxiga, Breztri |
| Medicure Pharma INC. | $91.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.22 | 2021-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $67.61 | 2022 | |
| Mayne Pharma Commercial LLC | $65.20 | 2021 | |
| Eisai INC. | $60.61 | 2021 | |
| Idorsia Pharmaceuticals US INC | $57.51 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $54.18 | 2021 | |
| Upsher-Smith Laboratories LLC | $41.31 | 2021 | |
| Radius Health, INC. | $33.99 | 2021-2022 | |
| Myovant Sciences INC. | $30.71 | 2022 | |
| Glaxosmithkline, LLC. | $29.44 | 2023 | Nucala |
| Ibsa Pharma INC. | $23.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.39 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.40 | 2023 | Inpefa |
| Ethicon US, LLC | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Allmaras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.